Geron (NASDAQ:GERN) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Geron (NASDAQ:GERN - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05, Briefing.com reports. The firm had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company's revenue for the quarter was up 17138.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) EPS.

Geron Price Performance

Shares of NASDAQ GERN traded down $0.07 during trading hours on Friday, reaching $4.22. 6,805,310 shares of the stock traded hands, compared to its average volume of 10,438,124. The company's 50-day simple moving average is $4.32 and its two-hundred day simple moving average is $4.30. The company has a market capitalization of $2.54 billion, a P/E ratio of -11.92 and a beta of 0.52. Geron has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GERN shares. HC Wainwright initiated coverage on Geron in a research report on Tuesday. They set a "buy" rating and a $8.00 target price for the company. Leerink Partnrs raised Geron to a "strong-buy" rating in a report on Monday, September 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Geron in a report on Friday, August 9th. Scotiabank assumed coverage on shares of Geron in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 target price for the company. Finally, StockNews.com upgraded shares of Geron to a "sell" rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.